Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head

自体骨髓抽吸浓缩液治疗股骨头坏死

基本信息

  • 批准号:
    10658324
  • 负责人:
  • 金额:
    $ 77.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-10 至 2028-07-31
  • 项目状态:
    未结题

项目摘要

Abstract/Project Summary Osteonecrosis of the femoral head (ONFH) is characterized by disrupted circulation within the bony compartment, leading to death of bone and marrow cells. It is associated with progressive pain, bony collapse, and joint degeneration within months to several years. Over 10 million people are afflicted worldwide. Most patients are diagnosed in their mid-30s, during their peak working years. The pathogenesis and treatment of this disease are controversial. If diagnosed early, the goal is to preserve the native hip joint. Total hip replacement is reserved for painful end-stage disease. Core decompression (CD) is the most common treatment in the early stages of ONFH and creates a drill tract into the lesion. However, the clinical outcome of CD is variable. There is increasing interest in using bone marrow aspirate concentrate (BMAC) to augment CD. Yet, studies have been limited to small case series, different disease stages, multiple risk factors, variable surgical techniques, or otherwise have lacked rigor. A randomized controlled trial (RCT) is needed to obtain a more definitive answer regarding the efficacy of BMAC with CD for early-stage ONFH. The overall goal of our multicenter clinical trial (U01) is to test the following hypotheses: “Patients who have early-stage ONFH undergoing CD augmented with autogenous BMAC will have better clinical and radiological outcomes than CD alone.” This RCT will also define specific patient characteristics that determine the long-term outcomes of these procedures. The Co-PIs are world-renowned experts, who are academic and clinical leaders in osteonecrosis. A team of highly recognized clinicians, who have expertise in the treatment of osteonecrosis from 12 centers in the United States have been recruited. For standardization, we will utilize a centralized radiologist, a central bone biology laboratory, and a center for data management and biostatistical analysis. Our specific aims are: Specific Aim 1 (SA1). To determine if CD with autogenous BMAC results in better outcomes than CD alone for the treatment of early-stage (pre-collapse) ARCO Stage I and II ONFH. Specific Aim 2 (SA2). SA 2A. To determine the cellular phenotype of the patients’ bone marrow aspirates, as assessed by Mass Cytometry by Time of Flight (CyTOF). SA 2B. To build a multivariate model classifying patients who have satisfactory and unsatisfactory clinical and/or radiological outcomes based on the combined mass cytometry cell frequency and functional feature dataset. In summary, we have planned this multicenter trial with our NIAMS-sponsored project team (R34 AR073505) and assembled a team of experts in the diagnosis and treatment of ONFH. The trial will benefit from existing studies and infrastructure by our group. We will determine if ON patients benefit from autogenous BMAC to augment CD, and investigate the biological mechanisms underlying improvements in outcome.
抽象/项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STUART B GOODMAN其他文献

STUART B GOODMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STUART B GOODMAN', 18)}}的其他基金

Customized MSCs to Enhance Healing of Bone Defects
定制间充质干细胞促进骨缺损的愈合
  • 批准号:
    10115615
  • 财政年份:
    2018
  • 资助金额:
    $ 77.91万
  • 项目类别:
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip
改善早期髋骨坏死治疗的组织工程方法
  • 批准号:
    10394866
  • 财政年份:
    2018
  • 资助金额:
    $ 77.91万
  • 项目类别:
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip
改善早期髋骨坏死治疗的组织工程方法
  • 批准号:
    9921203
  • 财政年份:
    2018
  • 资助金额:
    $ 77.91万
  • 项目类别:
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the Hip
改善早期髋骨坏死治疗的组织工程方法
  • 批准号:
    9594129
  • 财政年份:
    2018
  • 资助金额:
    $ 77.91万
  • 项目类别:
Customized MSCs to Enhance Healing of Bone Defects
定制间充质干细胞促进骨缺损的愈合
  • 批准号:
    9897409
  • 财政年份:
    2018
  • 资助金额:
    $ 77.91万
  • 项目类别:
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs
通过移植 NF-kB 驱动的免疫调节 MSC 增强植入物周围的骨愈合
  • 批准号:
    9528468
  • 财政年份:
    2012
  • 资助金额:
    $ 77.91万
  • 项目类别:
Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs
通过移植 NF-kB 驱动的免疫调节 MSC 增强植入物周围的骨愈合
  • 批准号:
    10222569
  • 财政年份:
    2012
  • 资助金额:
    $ 77.91万
  • 项目类别:
Wear Particle Disease and NF-kappa B Signaling
磨损颗粒病和 NF-kappa B 信号传导
  • 批准号:
    8419372
  • 财政年份:
    2012
  • 资助金额:
    $ 77.91万
  • 项目类别:
Wear Particle Disease and NF-kappa B Signaling
磨损颗粒病和 NF-kappa B 信号传导
  • 批准号:
    8543631
  • 财政年份:
    2012
  • 资助金额:
    $ 77.91万
  • 项目类别:
Wear Particle Disease and NF-kappa B Signaling
磨损颗粒病和 NF-kappa B 信号传导
  • 批准号:
    8733519
  • 财政年份:
    2012
  • 资助金额:
    $ 77.91万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 77.91万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
    Studentship
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
    Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
    Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
自体干细胞移植后的 HIV 储库和基因修饰细胞动力学
  • 批准号:
    10700521
  • 财政年份:
    2023
  • 资助金额:
    $ 77.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了